# Cannabis Dementia Treatment

**Published:** 2026-07-14T13:53:15.655Z  
**Topic:** Derive  
**Sentiment:** neutral  
**Publisher:** TrendWatcher — https://www.trendwatcher.in/article/6c08769f-8d7b-4d71-ae61-cef75ed04790

Cannabis-derived treatment eases agitation in 90% of dementia patients, with a THC-CBD combo showing promise in a small phase 2 trial, sparking hope for a new

A THC-CBD oil eased agitation in hospice-eligible dementia patients, with close to 90% improving after 12 weeks in a small phase 2 trial [1]. The study's findings have significant implications for the treatment of dementia, a condition that affects about 6.7 million Americans age 65 and older, a figure projected to reach 13.8 million by 2060 [1].

| At a glance | |
|---|---|
| Improvement rate | 90% |
| Trial duration | 12 weeks |
| Patient population | Hospice-eligible dementia patients |
| Formulation | THC-CBD oil suspension |

## Study Details
The LiBBY trial, short for Life’s end Benefits of cannaBidiol and tetrahYdrocannabinol, was presented at the Alzheimer’s Association International Conference in London [1]. The multicenter, randomized, double-blind, placebo-controlled study enrolled 120 participants with Alzheimer’s disease or another dementia, and the average age was 80 [1]. The study's primary outcome was assessed after two weeks, with follow-up at 12 weeks, and the results showed that the THC-CBD oil suspension eased agitation in hospice-eligible patients with advanced dementia [1].

## Context and Implications
The study's findings build on earlier work suggesting cannabinoids may help calm some people with dementia [1]. However, other studies have found that using medical or recreational marijuana to ease symptoms of numerous mental health conditions doesn't work [3]. The Alzheimer’s Association says there is very little scientific evidence on cannabis and cannabis-derived products in Alzheimer’s disease or other dementias, and that cannabis is not approved by the Food and Drug Administration for dementia treatment [1]. Researchers at the University of Kentucky are part of a groundbreaking clinical trial exploring the use of medical marijuana in managing symptoms of late-stage dementia [2].

## What to Watch
* Further research on the safety and effectiveness of cannabis-derived treatments for dementia
* The potential for policy changes that would allow patients and their caregivers greater access to cannabis-derived treatments
* The outcome of the LiBBY Study and its impact on the development of new treatments for dementia

The real significance of the study's findings lies in their potential to provide a new avenue of relief for patients and caregivers affected by dementia, a condition that currently has limited treatment options [2]. As researchers continue to explore the potential of cannabis-derived treatments, the question remains whether these findings will translate into meaningful improvements in patient outcomes and quality of life [1].

## Sources
1. Prismnews — [THC-CBD combo eases agitation in advanced dementia trial | Prism News](https://www.prismnews.com/news/thc-cbd-combo-eases-agitation-in-advanced-dementia-trial)
2. Research — [Easing agitation and fear: UK researchers study cannabis for late-stage dementia | UK Research](https://research.uky.edu/news/easing-agitation-and-fear-uk-researchers-study-cannabis-late-stage-dementia)
3. WMUR — [Scientists say marijuana doesn’t ease anxiety or other mental health conditions](https://www.wmur.com/article/marijuana-anxiety-mental-health/70770512)

---
Cite as: TrendWatcher, "Cannabis Dementia Treatment", https://www.trendwatcher.in/article/6c08769f-8d7b-4d71-ae61-cef75ed04790